Skip to main content
. 2023 Sep 15;3(9):1862–1874. doi: 10.1158/2767-9764.CRC-23-0087

FIGURE 5.

FIGURE 5

Clinical analysis of serum EphA2-NF levels for patients with pancreatic cancer treated with surgical resection or chemotherapy. Kaplan–Meier analyses of patients with pancreatic cancer treated with surgical resection (A) and chemotherapy (B) after classification into serum EphA2-NF–high (≥50 pg/mL) and –low (<50 pg/mL) groups. Kaplan–Meier analyses of patients with pancreatic cancer treated with surgical resection (C) and chemotherapy (D) classified into CA19-9–high (≥37 U/mL) and –low (<37 U/mL) groups. Kaplan–Meier analyses of patients with pancreatic cancer treated with GnP (E) and modified FOLFIRINOX (oxaliplatin, irinotecan, and 5-fluorouracil, mFFX) (F) after classification into serum EphA2-NF (≥50 pg/mL) and low (<50 pg/mL) groups. Kaplan–Meier analyses of patients with pancreatic cancer treated with GnP (G) and mFFX (F) classified into CA19-9–high (≥37 U/mL) and –low (<37 U/mL) groups.